Silverarc Capital Management, LLC Vertex Pharmaceuticals Inc Transaction History

Silverarc Capital Management, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	BUY	$338.18 - $362.46 $199,526 - $213,851	590 Added 4.48%	13,765 $4.79 Million
Q2 2023 Aug 14, 2023	SELL	$314.42 - $351.91 $1,886 - $2,111	-6 Reduced 0.05%	13,175 $4.64 Million
Q1 2023 May 15, 2023	BUY	$283.23 - $323.1 $508,964 - $580,610	1,797 Added 15.79%	13,181 $4.15 Million
Q4 2022 Feb 14, 2023	BUY	$285.76 - $321.48 $79,727 - $89,692	279 Added 2.51%	11,384 $3.29 Million
Q3 2022 Oct 28, 2022	BUY	$273.83 - $305.53 $189,216 - $211,121	691 Added 6.64%	11,105 $3.22 Million
Q2 2022 Jul 25, 2022	BUY	$234.96 - $292.55 $652,248 - $812,118	2,776 Added 36.34%	10,414 $2.94 Million
Q1 2022 May 13, 2022	BUY	$221.42 - $260.97 $584,105 - $688,438	2,638 Added 52.76%	7,638 $1.99 Million
Q4 2021 Feb 14, 2022	BUY	$177.01 - $223.45 $885,050 - $1.12 Million	5,000 New	5,000 $1.1 Million
Q2 2021 Aug 16, 2021	SELL	$187.49 - $221.1 $1.41 Million - $1.66 Million	-7,500 Closed	0 $0
Q1 2021 May 18, 2021	BUY	$207.02 - $241.31 $517,550 - $603,275	2,500 Added 50.0%	7,500 $1.61 Million
Q4 2020 Feb 16, 2021	BUY	$207.01 - $276.09 $1.04 Million - $1.38 Million	5,000 New	5,000 $1.18 Million

1,716

225M

1.19M

1.56M

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $129B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

Get notified when there are updates to the investment portfolio of Silverarc Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Silverarc Capital Management, LLC with notifications on news.